Cargando…

Pharmacotherapy for uveitis: current management and emerging therapy

Uveitis, a group of conditions characterized by intraocular inflammation, is a major cause of sight loss in the working population. Most uveitis seen in Western countries is noninfectious and appears to be autoimmune or autoinflammatory in nature, requiring treatment with immunosuppressive and/or an...

Descripción completa

Detalles Bibliográficos
Autores principales: Barry, Robert J, Nguyen, Quan Dong, Lee, Richard W, Murray, Philip I, Denniston, Alastair K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181632/
https://www.ncbi.nlm.nih.gov/pubmed/25284976
http://dx.doi.org/10.2147/OPTH.S47778
_version_ 1782337395726745600
author Barry, Robert J
Nguyen, Quan Dong
Lee, Richard W
Murray, Philip I
Denniston, Alastair K
author_facet Barry, Robert J
Nguyen, Quan Dong
Lee, Richard W
Murray, Philip I
Denniston, Alastair K
author_sort Barry, Robert J
collection PubMed
description Uveitis, a group of conditions characterized by intraocular inflammation, is a major cause of sight loss in the working population. Most uveitis seen in Western countries is noninfectious and appears to be autoimmune or autoinflammatory in nature, requiring treatment with immunosuppressive and/or anti-inflammatory drugs. In this educational review, we outline the ideal characteristics of drugs for uveitis and review the data to support the use of current and emerging therapies in this context. It is crucial that we continue to develop new therapies for use in uveitis that aim to suppress disease activity, prevent accumulation of damage, and preserve visual function for patients with the minimum possible side effects.
format Online
Article
Text
id pubmed-4181632
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-41816322014-10-03 Pharmacotherapy for uveitis: current management and emerging therapy Barry, Robert J Nguyen, Quan Dong Lee, Richard W Murray, Philip I Denniston, Alastair K Clin Ophthalmol Review Uveitis, a group of conditions characterized by intraocular inflammation, is a major cause of sight loss in the working population. Most uveitis seen in Western countries is noninfectious and appears to be autoimmune or autoinflammatory in nature, requiring treatment with immunosuppressive and/or anti-inflammatory drugs. In this educational review, we outline the ideal characteristics of drugs for uveitis and review the data to support the use of current and emerging therapies in this context. It is crucial that we continue to develop new therapies for use in uveitis that aim to suppress disease activity, prevent accumulation of damage, and preserve visual function for patients with the minimum possible side effects. Dove Medical Press 2014-09-22 /pmc/articles/PMC4181632/ /pubmed/25284976 http://dx.doi.org/10.2147/OPTH.S47778 Text en © 2014 Barry et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Barry, Robert J
Nguyen, Quan Dong
Lee, Richard W
Murray, Philip I
Denniston, Alastair K
Pharmacotherapy for uveitis: current management and emerging therapy
title Pharmacotherapy for uveitis: current management and emerging therapy
title_full Pharmacotherapy for uveitis: current management and emerging therapy
title_fullStr Pharmacotherapy for uveitis: current management and emerging therapy
title_full_unstemmed Pharmacotherapy for uveitis: current management and emerging therapy
title_short Pharmacotherapy for uveitis: current management and emerging therapy
title_sort pharmacotherapy for uveitis: current management and emerging therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181632/
https://www.ncbi.nlm.nih.gov/pubmed/25284976
http://dx.doi.org/10.2147/OPTH.S47778
work_keys_str_mv AT barryrobertj pharmacotherapyforuveitiscurrentmanagementandemergingtherapy
AT nguyenquandong pharmacotherapyforuveitiscurrentmanagementandemergingtherapy
AT leerichardw pharmacotherapyforuveitiscurrentmanagementandemergingtherapy
AT murrayphilipi pharmacotherapyforuveitiscurrentmanagementandemergingtherapy
AT dennistonalastairk pharmacotherapyforuveitiscurrentmanagementandemergingtherapy